Minimal clinically important difference in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung disease with an estimated median survival of 2–5 years and a significant impact on quality of life (QoL). Current approved medications, pirfenidone and nintedanib, have shown a reduction in annual decline of forced vital ca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2021-06-01
|
| Series: | Breathe |
| Online Access: | http://breathe.ersjournals.com/content/17/2/200345.full |